Ionis Pharmaceuticals Announced That It Has Entered Into A License Agreement Under Which Sobi Receives Exclusive Rights In Countries Outside The U.S., Canada And China To Commercialize Olezarsen As A Potential Treatment For Familial Chylomicronemia Syndro